ReviewCureus2020
Romiplostim and Eltrombopag in Immune Thrombocytopenia as a Second-Line Treatment.
Review in Cureus, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07093606 (Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura), which is not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura
Who cites it
10 citing papers in PubMed, 18 citations in OpenAlex.
- A Comparative Analysis of the Efficacy, Safety and Mechanism of Action of Flebogamma DIF, Fostamatinib and Romiplostim in Immune Thrombocytopenia.Life (Basel, Switzerland) · 2026Review
- Romiplostim during pregnancy in refractory primary immune thrombocytopenia: Literature review and case series.Therapeutic advances in hematology · 2026Article
- Impact of Primary Chronic Immune Thrombocytopenia and Thrombopoietin Receptor Agonists Treatment Instructions on Daily Living: Results of a Multinational Cross-Sectional Survey.Patient preference and adherence · 2025Article
- Experience with Pediatric Chronic Immune Thrombocytopenia over 30 Years in the Era before Eltrombopag.Children (Basel, Switzerland) · 2024Article
- Clinical Care Team's Guide for Awareness on Risk Assessment of Eltrombopag Complicating Acute Kidney Injury in Relapsed Immune Thrombocytopenic Patients: A Case Report.Medicina (Kaunas, Lithuania) · 2023Article
- Therapeutic Outcomes of High Dose-Dexamethasone versus Prednisolone + Azathioprine, Rituximab, Eltrombopag, and Romiplostim Strategies in Persistent, Chronic, Refractory, and Relapsed Immune Thrombocytopenia Patients.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Evaluation of the effect of eltrombopag therapy on the platelet collagen receptor glycoprotein VI (GPVI) expression and soluble GPVI levels in young patients with immune thrombocytopenia.Journal of thrombosis and thrombolysis · 2023Article
- Article
- Article
- Eltrombopag and its beneficial role in management of ulcerative Colitis associated with ITP as an upfront therapy case report.Clinical case reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by platelet count less than 100×10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.